These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
515 related items for PubMed ID: 33068176
21. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Shao B, Wang X, Zhang L, Li D, Liu X, Song G, Cao H, Zhu J, Li H. Technol Cancer Res Treat; 2019 Jan 01; 18():1533033819828709. PubMed ID: 30786836 [Abstract] [Full Text] [Related]
22. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. Gong C, Tan W, Chen K, You N, Zhu S, Liang G, Xie X, Li Q, Zeng Y, Ouyang N, Li Z, Zeng M, Zhuang S, Lau WY, Liu Q, Yin D, Wang X, Su F, Song E. EBioMedicine; 2016 Sep 01; 11():199-209. PubMed ID: 27566954 [Abstract] [Full Text] [Related]
23. Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer. Guo J, Liu C, Wang W, Liu Y, He H, Chen C, Xiang R, Luo Y. PLoS One; 2018 Sep 01; 13(7):e0200716. PubMed ID: 30048472 [Abstract] [Full Text] [Related]
24. Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. Tural D, Serdengecti S, Demirelli F, Öztürk T, İlvan S, Turna H, Özgüroglu M, Büyükünal E. Br J Cancer; 2014 Apr 15; 110(8):1968-76. PubMed ID: 24595002 [Abstract] [Full Text] [Related]
28. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S. JAMA Oncol; 2015 Jul 15; 1(4):448-54. PubMed ID: 26181252 [Abstract] [Full Text] [Related]
29. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response. Xing AY, Wang B, Li YH, Chen X, Wang YW, Liu HT, Gao P. Pathol Oncol Res; 2021 Jul 15; 27():1609753. PubMed ID: 34257614 [Abstract] [Full Text] [Related]
30. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy. Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, Ye J, Zhang S, Zhang H, Zhu S, Li T, Liu Y. Breast Cancer Res Treat; 2015 Nov 15; 154(2):239-49. PubMed ID: 26498019 [Abstract] [Full Text] [Related]
33. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Li HY, Liang JL, Kuo YL, Lee HH, Calkins MJ, Chang HT, Lin FC, Chen YC, Hsu TI, Hsiao M, Ger LP, Lu PJ. Breast Cancer Res; 2017 Dec 19; 19(1):133. PubMed ID: 29258605 [Abstract] [Full Text] [Related]